In a recently published bipartisan report, representatives Diana DeGette, D-Colorado, and Tom Reed, R-New York, co-chairs of the Congressional Diabetes Caucus, released findings from a year-long inquiry into the sources of ever-increasing insulin prices.
In a recently published bipartisan report, representatives Diana DeGette, D-Colorado, and Tom Reed, R-New York, co-chairs of the Congressional Diabetes Caucus, released findings from a year-long inquiry into the sources of ever-increasing insulin prices.
The inquiry provided an overview of the nuances in the insulin market as compared with the traditional prescription drug market, and policy recommendations aimed at lowering insulin prices. Since 2012, the average price of insulin has nearly doubled, leading many Americans who rely on the lifesaving medication unable to afford the drug.
In order to address high insulin prices, the inquiry offered several policy changes, including:
1. Combatting upward prices by encouraging the development and use of value-based contracts between insulin makers and pharmacy benefit managers (PBMs). The authors noted that value-based contracts are a delivery-based contract that is able to bring down costs. This is because they create an arrangement between different entities along the supply chain that pay higher rates for better patient health outcomes, instead of for higher sale volume. Implementing value-based contracts in the insulin space could lower list prices.
2. Changing competitive market forces by encouraging the development of follow-on insulin drugs by addressing patent extensions. The first follow-on insulin product was approved by the FDA in 2015. These drugs, formulated as cheaper versions of branded insulins, could provide a cost savings to patients if there were more available on the market. To expedite the approval process, the Congressional Diabetes Caucus recommended that the FDA allow exceptions or fast-track approval for certain follow-on insulin products if they are off-patent and meet certain quality and comparative effectiveness standards.
3. Require manufacturers to disclose their insulin’s list pricing process. The Congressional Diabetes Caucus suggested that Congress introduce transparency legislation that would require drug manufacturers to disclose how their insulin prices are set. This action would in turn place potential downward pressure on list prices.
4. Cap out-of-pocket expenses for prescription drugs that are needed for chronic conditions. Chronic conditions such as diabetes are long-lasting that may get worse over time. As such, patients with similar disease must take prescription drugs throughout their lives in order to manage their conditions. By capping out-of-pocket costs for life-sustaining drugs, such as insulin, it would help patients better manage their disease and avoid adverse effects.
To learn more about follow-on insulin products, click here.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
"Not So Different": How the BPCIA Transition Will Affect Biosimilar Uptake
April 10th 2020This week on the podcast, we’re speaking with the executive director of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), Cate Lockhart, PharmD, PhD, about the acceptance process for biosimilars in the United States, what BBCIC is doing to help the market develop, and how the new approval pathway for biologics will affect the pace at which biosimilars come to market.
Analyzing Safety of Switching From Originators to Biosimilars: A Meta-Analysis of 21 Trials
February 10th 2024The authors of a meta-analysis assessing several disease states found no significant differences in serious adverse events, deaths, or treatment discontinuations between patients who switched from reference products to biosimilars and those who did not.
Report: Varied Biosimilar Uptake Speeds Pose Missed Opportunities for Cost Savings
January 23rd 2024Samsung Bioepis’ Biosimilar Market Report for the first quarter of 2024 chronicles some major market trends, including which treatment spaces have quicker uptake than others, highlighting missed opportunities for savings as well as the 1-year experience of adalimumab biosimilar competition in the US.
IQVIA Projects $192 Billion Loss for Originators by 2028 Thanks to Biosimilar, Generic Competition
January 18th 2024The IQVIA Institute for Human Data Science’s most recent Global Use of Medicines report projected that market introductions of new biosimilar and generic drugs will increase projected losses for originator products from $111 billion to $192 billion over the next 5 years.
IQVIA Report Flags Challenges With Biosimilar Access, Savings Throughout Europe
January 10th 2024IQVIA’s report on the impact biosimilar competition has had on Europe’s health care space identified ongoing challenges with biosimilar access and generating savings, calling for more policies focusing on fostering a sustainable market for years to come.